STUDY DESIGN Controlled animal experiments. OBJECTIVE To test the dose and efficacy of teriparatide in a rat spinal fusion model. SUMMARY OF BACKGROUND DATA Teriparatide was shown to enhance spinal fusion in rats and rabbits previously, but the dose-dependent effect of teriparatide in spinal fusion in rats was not well characterized. METHODS A 0.5 × 0.5 cm trabecular bone graft was taken ...

OBJECTIVE To evaluate the responses of serum beta-CTX and osteocalcin in patients who were undergoing treatment with teriparatide or strontium ranelate (SR). SUBJECTS AND METHODS We analyzed 14 patients (12 women and 2 men; mean age of 71 years) taking teriparatide, and 13 female patients (mean age of 70 years) taking SR; all the patients having previously been on bisphosphonates. Serum beta-...

n engl j med 358;12 www.nejm.org march 20, 2008 1304 approved indications in postmenopausal and male osteoporosis, we recommended that teriparatide be considered for patients at high risk for fracture who require sustained use of glucocorticoids and who have either osteoporosis or low bone mass with a prevalent fracture. In his editorial, Sambrook suggests the use of teriparatide as a firstline...

INTRODUCTION While teriparatide is the only skeletal anabolic agent approved in the United States, treatment failure is a major concern which complicates its clinical utility. We sought to identify factors that predict response failure in patients with low bone mass. METHOD We performed a retrospective study of adults with osteopenia or osteoporosis (T-scores < - 1.0 and - 2.5 SD below normal...

OBJECTIVE To determine the effect of teriparatide on new bone formation in a rat model of distraction osteogenesis. METHODS The experimental study was conducted at the Aga Khan University Hospital, Karachi, in November-December 2010, and comprised male Sprague-Dawley rats weighing 250gm each who were allocated to two treatment groups, teriparatide and saline, both given subcutaneously for 7 w...

CONTEXT Current osteoporosis medications increase bone mineral density (BMD) modestly and reduce, but do not eliminate, fracture risk. Attempts to improve efficacy by administering anabolic agents and bisphosphonates concomitantly have been unsuccessful. Conversely, 12 months of concomitant denosumab and teriparatide therapy increases BMD more than either drug alone. OBJECTIVE The purpose of ...

OBJECTIVES To describe fracture rates, back pain, and health-related quality of life (HRQoL) in postmenopausal women with osteoporosis and prior bisphosphonate therapy, treated with teriparatide for up to 18 months and followed up for a further 18 months. DESIGN Prospective, multinational, and observational study. METHODS Data on prior bisphosphonate use, clinical fractures, back pain visua...

All therapies currently recommended for the management of osteoporosis act mainly to inhibit bone resorption and reduce bone remodeling. Parathyroid hormone and its analog, teriparatide (recombinant human PTH(1-34), represent a new class of anabolic therapies for the treatment of severe osteoporosis, having the potential to improve skeletal micro-architecture. Significant reductions in both ver...

All therapies currently recommended for the management of osteoporosis act mainly to inhibit bone resorption and reduce bone remodeling. PTH and its analog, teriparatide [recombinant human PTH(1-34)], represent a new class of anabolic therapies for the treatment of severe osteoporosis, having the potential to improve skeletal microarchitecture. Significant reductions in both vertebral and appen...